| Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference |
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference. |
businesswire.com |
2025-02-27 03:00:00 |
Czytaj oryginał (ang.) |
| Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion |
Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025. Company actively seeking to establish a collaboration agreement with a pharmaceutical company to initiate a phase 3 study using lacutamab to target patients with Cutaneous T-Cell Lymphoma. |
seekingalpha.com |
2025-02-20 13:39:25 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome |
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome. |
businesswire.com |
2025-02-17 03:02:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors |
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4. IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesi. |
businesswire.com |
2025-01-27 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York |
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York. |
businesswire.com |
2025-01-21 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces Transformative Strategy to Accelerate Growth |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. "Our updated strategy underscores Innate Pharma's unwavering dedication to innovation, collaboration, and delivering transformative th. |
businesswire.com |
2025-01-10 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA. Jonathan Dickinson, Chief Executive Officer of Innate Pharma, will represent the Company in a session scheduled Tuesday, January 14, 2025 from 11:15 - 11:55 am PST. Other Executive Boar. |
businesswire.com |
2024-12-20 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The TELLOMAK study addresses a critical unmet need for p. |
businesswire.com |
2024-12-09 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma |
MARSEILLE, France & DIAMOND BAR, Calif.--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL). Innate's ongoing Phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplas. |
businesswire.com |
2024-12-06 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET® asset, have been selected for the American Society of hematology (ASH) Annual Meeting. “We are proud of the progress being made across our multiple programs, including our lead proprietary asset l. |
businesswire.com |
2024-12-03 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma: Looking Like A Company We'll Regret Ignoring |
Innate has a stable of interesting pipeline projects in development for a range of cancers. The most advanced candidate is poised for a potential accelerated approval for cutaneous T-cell lymphoma. Other programs, including those partnered with big pharma, are beginning to show signs of promise in non-heme malignancies as well. |
seekingalpha.com |
2024-11-25 13:54:45 |
Czytaj oryginał (ang.) |
| Innate Pharma Releases Its 2025 Financial Calendar |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2025 financial calendar: March 27, 2025: Publication of 2024 financial statements May 13, 2025: Publication of revenue and cash position for 1Q2025 May 22, 2025: Annual General Shareholders Meeting September 17, 2025: Publication of half year financial statements November 13, 2025: Publication of revenue and cash position for 3Q2025 All financi. |
businesswire.com |
2024-11-20 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501 |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate's proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654). The data published shows that IPH65. |
businesswire.com |
2024-11-19 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript |
Innate Pharma S.A. (NASDAQ:IPHA ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Henry Wheeler - Vice President, Investor Relations and Communications Jonathan Dickinson - Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yannis Morel - Chief Operating Officer Frederic Lombard - Chief Financial Officer Arvind Sood - Executive Vice President U.S. Operations Conference Call Participants Daina Graybosch - Leerink Partners Rajan Sharma - Goldman Sachs Arthur He - HCW Operator Hello and thank you for standing by. |
seekingalpha.com |
2024-11-13 15:09:18 |
Czytaj oryginał (ang.) |
| Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2024. "I'm honored to join Innate Pharma at such a pivotal moment in its evolution,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We achieved notable regulatory milestones during the quarter including encouraging initial feedback from the FDA for lacutama. |
businesswire.com |
2024-11-13 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will be presented at the SITC Annual Meeting 2024. “We are thrilled to share our latest preclinical data at the SITC Annual Meeting, highlighting the potential of IPH6501, our tetra-spe. |
businesswire.com |
2024-11-08 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates |
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for third quarter 2024 results and business updates. |
businesswire.com |
2024-11-07 03:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces Its Participation in Upcoming Investor Conferences |
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences. |
businesswire.com |
2024-10-29 04:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vi. |
businesswire.com |
2024-10-14 05:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 |
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024. |
businesswire.com |
2024-09-30 05:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors |
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502, its novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 in solid tumors. Innate expects to initiate the Phase 1 study in the coming months. The P. |
businesswire.com |
2024-09-23 05:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript |
Innate Pharma S.A. (NASDAQ:IPHA ) Q2 2024 Earnings Conference Call September 12, 2024 8:00 AM ET Company Participants Henry Wheeler - Vice President, Investor Relations and Communications Herve Brailly - Interim Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yannis Morel - Chief Operating Officer Frederic Lombard - Chief Financial Officer Arvind Sood - Executive Vice President U.S. Operations Conference Call Participants Rajan Sharma - Goldman Sachs Daina Graybosch - Leerink Partners Ashiq Mubarack - Citi Swayampakula Ramakanth - HCW Operator Thank you for standing by, and welcome to the Innate Pharma First-Half 2024 Financial Results and Business Update. |
seekingalpha.com |
2024-09-12 15:19:06 |
Czytaj oryginał (ang.) |
| Innate Pharma Reports First Half 2024 Business Update and Financial Results |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2024. The consolidated financial statements are attached to this press release. “We are focused on our growth strategy as we advance our pipeline,” said Hervé Brailly, Chief Executive Officer ad interim of Innate Pharma. “We recently presented Phase 2 results with lacutamab in myc. |
businesswire.com |
2024-09-12 05:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2024. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice. |
businesswire.com |
2024-09-05 05:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference |
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference. |
businesswire.com |
2024-09-04 05:00:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Announces Its Participation in Upcoming Investor Conference |
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conference. |
businesswire.com |
2024-08-01 05:00:00 |
Czytaj oryginał (ang.) |